MOB-015 is recommended for approval in EU
STOCKHOLM, June 28[th], 2023, Moberg Pharma AB (OMX:MOB) hereby announces that the Decentralized Procedure has ended with a positive outcome and that MOB-015 is recommended for national approval in 13 European countries for the treatment of mild to moderate fungal infections of the nails in adults.· The approval in the European Union represents the first marketing authorizations for Moberg Pharma´s new onychomycosis treatment worldwide · Approval is supported by two Phase 3 trials where MOB-015 demonstrated superior levels of mycological cure (76% vs up to 42% for comparators), and a